Clinical Trials Logo

Filter by:
NCT ID: NCT00714038 Completed - Asthma Clinical Trials

CARE - Quality Improvement in Asthma Secondary Prevention in Primary Care, Through Delegation of Consultations to the Nurse.

Start date: May 2008
Phase: N/A
Study type: Observational

Quality Improvement in Primary Care: delegation of check-ups to nurses in general practice

NCT ID: NCT00713960 Completed - Clinical trials for Cardiovascular Disease

CARE - Quality Improvement in Cardiovascular Secondary Prevention in Primary Care, Through Delegation of Consultations to the Nurse.

Start date: April 2008
Phase: N/A
Study type: Observational

Quality Improvement in Primary Care: delegation of check-ups to nurses in general practice

NCT ID: NCT00713518 Completed - Clinical trials for Age Related Macular Degeneration

Phase II Open Label Multicenter Study For Age Related Macular Degeneration Comparing PF-04523655 Versus Lucentis In The Treatment Of Subjects With CNV (MONET Study).

MONET
Start date: November 2009
Phase: Phase 2
Study type: Interventional

The aim of the study is to evaluate whether PF-04523655 is effective in the treatment of neovascular/wet AMD and at which dose.

NCT ID: NCT00713440 Completed - Clinical trials for Type 2 Diabetes Mellitus

Incretin Physiology Associated With Steroid Hormone Treatment

Start date: July 2008
Phase: N/A
Study type: Interventional

The purpose of this study is to evaluate whether the reduced incretin effect and the paradoxical glucagon responses during oral glucose ingestion and isoglycaemic iv glucose infusion observed in patients with type 2 diabetes are causes (non-inducible in lean healthy subjects without family history of diabetes) or consequences (inducible) of the diabetic state.

NCT ID: NCT00711503 Completed - Type 1 Diabetes Clinical Trials

Anti-Interleukin-1 in Diabetes Action

AIDA
Start date: January 2009
Phase: Phase 2/Phase 3
Study type: Interventional

A draw trial of the effect of Interleukin-1 Receptor Antagonist (anakinra, Kineret®) on the insulin production in patients with new onset Type 1 diabetes. Kineret® is already being used in the treatment of patients suffering from rheumatoid arthritis and preclinical studies are now suggesting that it may also be useful for patients with Type 1 diabetes. The active substance in Kineret is interleukin-1 receptor antagonist, a blocker of an immune-signal molecule named interleukin-1. The trial is a blinded randomised trial, in which the patient is allocated to receive the active drug (Kineret®) or placebo (saline). The hypothesis is that anti-IL-1 treatment as add-on therapy to conventional insulin therapy will preserve or enhance beta-cell function.

NCT ID: NCT00711178 Completed - Actinic Keratoses Clinical Trials

A Randomized Multicenter Study of Daylight Mediated Photodynamic Therapy (PDT)

Start date: June 2008
Phase: N/A
Study type: Interventional

A randomised, multi-center study of daylight mediated photodynamic therapy (PDT) with Metvix in patients with multiple actinic keratosis on the face and/or scalp.

NCT ID: NCT00711048 Completed - Pain Clinical Trials

Esophageal Hypersensitivity Study in Healthy Volunteers

Start date: June 2008
Phase: Phase 1
Study type: Interventional

The purpose of the study is to compare sensitivity and sensitization of visceral pain in the esophagus using different pain stimuli

NCT ID: NCT00709384 Completed - Atrial Flutter Clinical Trials

Prevention of Atrial Tachycardia After a Right Atriotomy II

Start date: January 2006
Phase: Phase 2
Study type: Interventional

The investigators performed a prophylactic peroperative linear lesions connecting the tricuspid annulus with a right atriotomy and the atriotomy with the inferior caval vein to prevent atrial flutter on 15 consecutive adult patients undergoing surgery for congenital heart disease. Conduction time between electrodes placed on both sides of the lesions is measured on the second postoperative day. Coronary angiography and electrophysiology study using an electroanatomic mapping system to assess conduction across the line are performed three month after the operation.

NCT ID: NCT00707382 Completed - Schizophrenia Clinical Trials

Effect of Genotyping for CYP450 Polymorphisms Versus Intense Clinical Monitoring on Antipsychotic Drug Treatment

Start date: February 2008
Phase: N/A
Study type: Interventional

The purpose of this study is to determine whether genotyping for CYP2D6 and 2C19 polymorphisms or intense clinical monitoring of treatment and adverse effects improves the antipsychotic treatment in patients with schizophrenia. This study is designed as a three-armed prospective randomized controlled clinical trial and includes 300 patients with schizophrenia. Patients are followed for a period of one year. During the study period the following effect measures are registered: - Time to discontinuation of all antipsychotic medications - Number of changes in medication dose - Number of changes in medication - Compliance (patients´ adherence to medical treatment) - Clinical symptoms - Adverse effects

NCT ID: NCT00707330 Completed - Oxidative Stress Clinical Trials

Study of the Ability of Clarithromycin to Induce Oxidative Stress

CLAROX
Start date: May 2008
Phase: Phase 1
Study type: Interventional

The purpose of the study is to examine whether Klacid® (Clarithromycin) will induce oxidative stress (stress from oxygen) in healthy subjects. This is done by measuring the content of a particular substance in the urine sample, which is released when the body is exposed to oxidative stress. In addition, there will also be taken blood samples, which is analysed for another substance that is indicative of oxidative stress.